(Q34479906)

2 August 2017

1 reference

title

Against the clock towards new Ebola virus therapies (English)

1 reference

2 August 2017

main subject

Orthoebolavirus zairense

0 references

author

Carles Martínez-Romero

object named as

Carles Martínez-Romero

series ordinal

1

0 references

Adolfo García-Sastre

object named as

Adolfo García-Sastre

series ordinal

2

0 references

publication date

6 June 2015

1 reference

2 August 2017

1 reference

2 August 2017

volume

209

1 reference

2 August 2017

page(s)

4-10

1 reference

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Ebolavirus and Marburgvirus: insight the Filoviridae family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Emergence of Zaire Ebola Virus Disease in Guinea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Emerging targets and novel approaches to Ebola virus prophylaxis and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

7 January 2021

New uses for old drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Clinical management of filovirus-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Infectious disease. Ebola vaccine: little and late

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

7 January 2021

Ebola haemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

The contributions of Paul Ehrlich to infectious disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

RNA polymerase I-driven minigenome system for Ebola viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

7 January 2021

Current ebola vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Minigenome-based reporter system suitable for high-throughput screening of compounds able to inhibit Ebolavirus replication and/or transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Diagnosis and treatment of acute promyelocytic leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Ebola vaccine--an urgent international priority

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

How the current West African Ebola virus disease epidemic is altering views on the need for vaccines and is galvanizing a global effort to field-test leading candidate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Ebola virus vaccines: an overview of current approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Virus-like glycodendrinanoparticles displaying quasi-equivalent nested polyvalency upon glycoprotein platforms potently block viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Recent advances in Ebolavirus vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Favipiravir (T-705) inhibits in vitro norovirus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Improving siRNA bio-distribution and minimizing side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Clinical illness and outcomes in patients with Ebola in Sierra Leone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

An enzymatic virus-like particle assay for sensitive detection of virus entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2015.05.025

10.1016/J.VIRUSRES.2015.05.025

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference